The global gene therapy in CNS disorder market is expected to garner a market value of US$ 8.2 Billion in 2023 and is expected to accumulate a market value of US$ 113.04 Billion by registering a CAGR of 30% in the forecast period 2023 to 2033. The market for gene therapy in CNS disorders registered a CAGR of 19% in the historical period 2018 to 2022.
The gene therapy market for CNS disorders is rapidly growing, with a focus on delivering therapeutic genes directly to the brain to treat neurological conditions. The Gene Therapy in CNS Disorder market is a segment of the healthcare industry that deals with the effective management of the condition. The Gene Therapy in CNS Disorder market offers a range of products and services for its effective management and treatments. The most common CNS disorders being targeted by gene therapy include Parkinson's disease, Alzheimer's disease, Spinal Muscular Atrophy (SMA), Huntington's disease, and ALS (Amyotrophic Lateral Sclerosis).
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 8.2 billion |
| Anticipated Forecast Value (2033) | US$ 113.04 billion |
| Projected Growth Rate (2023 to 2033) | 30% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for gene therapy in CNS disorder reflected a value of 19% during the historical period, 2018 to 2022. During this period, the demand for gene therapy for CNS disorders increased due to the rising prevalence of these disorders, advancements in gene therapy technology, increasing awareness among healthcare providers and patients, and regulatory support. The market for Gene Therapy in CNS Disorder is gaining prominence as several companies are investing heavily in research and development of these therapies, resulting in the development of new treatment options for conditions such as Parkinson's disease, Alzheimer's disease, SMA, and ALS.
Looking ahead to the period from 2023 to 2033, the gene therapy market for CNS disorders is expected to continue growing. The increasing prevalence of CNS disorders and the rising demand for effective treatments are expected to drive demand for gene therapy in this space. Furthermore, the increasing investment in research and development of gene therapy for CNS disorders, along with the increasing regulatory support, is expected to result in the development and approval of more gene therapies for these conditions.
Overall, the gene therapy market for CNS disorders is expected to experience strong demand from 2023 to 2033, driven by several factors such as the increasing prevalence of these conditions, advancements in technology, growing awareness, and regulatory support. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies are creating awareness of Gene Therapy in CNS Disorder, fuelling the market growth. Thus, the market for Gene Therapy in CNS Disorder is expected to register a CAGR of 30% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The global gene therapy in CNS disorder market is primarily driven by an increased prevalence of CNS disorders such as, such as Parkinson's disease, Alzheimer's disease, and ALS, which is on the rise, which is driving the demand for effective treatments.
Up to 1 billion people, nearly one in six of the world’s population, suffer from neurological disorders, from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy to migraine, brain injuries and neuroinfections, with some 6.8 million dying of the maladies each year, according to a new United Nations report.
There have been significant advancements in gene therapy technology, including the development of viral vectors that can deliver therapeutic genes to the brain more efficiently and safely. Additionally, the growth of the Gene Therapy in CNS Disorder market is owed to ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with CNS disorders. There is a growing investment in research and development of gene therapy for CNS disorders, with many biotech and pharmaceutical companies working on developing new gene therapies for these conditions.
For instance, in June 2021, Alcyone Therapeutics announced its launch and receipt of $23 million in funding from funds affiliated with RTW Investments, LP. Alcyone is a biotechnology company dedicated to developing precision therapies for severe neurological conditions that impact patients and their families. Alcyone partnered with the Abigail Wexner Research Institute at Nationwide Children's Hospital to combine its proprietary next-generation CNS delivery platform and product development, manufacturing, and commercialization capabilities with AWRI's four gene therapy technologies and research and early development capabilities.
As more effective treatments become available, patients with CNS may experience better health outcomes and quality of life. This could increase demand for management options and further drive market growth.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The market is projected to get significantly affected by challenging factors such as Complexity of delivery, Immune responses, Safety concerns, Regulatory challenges, and Ethical considerations. Delivering therapeutic genes to the brain is a complex process, as the blood-brain barrier can prevent the delivery of gene therapy vectors to the targeted cells in the brain. The development of efficient delivery systems that can overcome this challenge is crucial for the success of gene therapy in CNS disorders.
Furthermore, gene therapy raises several ethical considerations, including the potential for unintended consequences or the development of genetic enhancements that may have social and ethical implications. Additionally, regulatory hurdles can limit the speed of development and availability of gene therapy treatments for CNS disorders.
Increasing Focus on R&D Shaping Landscape for Gene Therapy in CNS Disorders
The gene therapy market for CNS disorders is still in its early stages in the South and East Asian regions, but there is increasing interest in this field and several companies are actively engaged in research and development of gene therapies for CNS disorders in these regions. The South & East Asia region is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period.
The regulatory landscape for gene therapy in the South and East Asian region is evolving, with several countries adopting guidelines for the approval and regulation of gene therapy. For example, the Indian Council of Medical Research (ICMR) recently released guidelines for the ethical, legal and regulatory aspects of gene therapy research and clinical trials in India.
Increasing Focus on Technological Advancements shaping Landscape for Gene Therapy in CNS Disorder in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the high prevalence of CNS disorders in North America, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, which has led to a strong demand for new treatments. Additionally, North America has a well-developed healthcare infrastructure, along with a high level of research and development, significant investment, and a supportive regulatory environment.
The United States of America, in particular, has been experiencing an increase in CNS disorders related deaths, which may drive demand for treatment. The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, and high level of healthcare expenditure leading to a large patient population are some of the factors responsible for the growth of the market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Alzheimer’s disease to hold a significant share and push market growth
According to Future Market Insights, Alzheimer's disease, in particular, is likely to account for a significant share of the gene therapy in CNS disorders market. This is due to the high prevalence of neurodegenerative disorders.
Alzheimer's disease is a progressive and incurable neurodegenerative disorder that affects millions of people worldwide. It is the most common cause of dementia in the elderly, and the prevalence of the disease is expected to rise in the coming years due to an aging population.
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the gene therapy in CNS disorder treatment facilitates the growth of this segment.
Majority of the serious diseases involving the nervous system are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 8.2 billion |
| Market Value in 2033 | US$ 113.04 billion |
| Growth Rate | CAGR of 30% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is valued at US$ 8.2 billion in 2023.
Novartis AG, Bluebird Bio Inc., and Biogen are key market players.
The market is forecast to register a CAGR of 30.0% through 2033.
North America is likely to generate 40% revenue in 2033.
Significant advancements in gene therapy technology is encouraging the market growth.
1. Executive Summary | Gene Therapy in CNS Disorder Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
5.3.1. Alzheimer's Disease
5.3.2. Huntington's Disease
5.3.3. Parkinson's Disease
5.3.4. Batten Disease
5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Ex Vivo
6.3.2. In Vivo
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End Users , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.4. Y-o-Y Growth Trend Analysis By End Users , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End Users , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Indication
9.2.3. By Type
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Type
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Indication
10.2.3. By Type
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Type
10.3.4. By End Users
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Indication
11.2.3. By Type
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Type
11.3.4. By End Users
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Indication
12.2.3. By Type
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Type
12.3.4. By End Users
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Indication
13.2.3. By Type
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Type
13.3.4. By End Users
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Indication
14.2.3. By Type
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Indication
14.3.3. By Type
14.3.4. By End Users
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Indication
15.2.3. By Type
15.2.4. By End Users
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Indication
15.3.3. By Type
15.3.4. By End Users
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Indication
16.1.2.2. By Type
16.1.2.3. By End Users
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Indication
16.2.2.2. By Type
16.2.2.3. By End Users
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Indication
16.3.2.2. By Type
16.3.2.3. By End Users
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Indication
16.4.2.2. By Type
16.4.2.3. By End Users
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Indication
16.5.2.2. By Type
16.5.2.3. By End Users
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Indication
16.6.2.2. By Type
16.6.2.3. By End Users
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Indication
16.7.2.2. By Type
16.7.2.3. By End Users
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Indication
16.8.2.2. By Type
16.8.2.3. By End Users
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Indication
16.9.2.2. By Type
16.9.2.3. By End Users
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Indication
16.10.2.2. By Type
16.10.2.3. By End Users
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Indication
16.11.2.2. By Type
16.11.2.3. By End Users
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Indication
16.12.2.2. By Type
16.12.2.3. By End Users
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Indication
16.13.2.2. By Type
16.13.2.3. By End Users
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Indication
16.14.2.2. By Type
16.14.2.3. By End Users
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Indication
16.15.2.2. By Type
16.15.2.3. By End Users
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Indication
16.16.2.2. By Type
16.16.2.3. By End Users
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Indication
16.17.2.2. By Type
16.17.2.3. By End Users
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Indication
16.18.2.2. By Type
16.18.2.3. By End Users
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Indication
16.19.2.2. By Type
16.19.2.3. By End Users
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Indication
16.20.2.2. By Type
16.20.2.3. By End Users
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Indication
16.21.2.2. By Type
16.21.2.3. By End Users
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Indication
17.3.3. By Type
17.3.4. By End Users
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Voyager Therapeutics
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Spark Therapeutics
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Novartis AG
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Bluebird bio, Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Biogen
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Pfizer Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Rapa Therapeutics
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. BrainStorm Cell Therapeutics
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Eli Lilly and Company
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. UniQure Biopharma
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Gene Therapy in CNS Disorder Market
